



Glioblastoma in Adults: Current Management and Future Directions

Guest Editors:

Dr. Thomas Graillon

Department of Neurosurgery,
Hospital La Timone, Aix Marseille
Univ, APHM, Marseille, France

Dr. Sebastien Boissonneau

Department of Neurosurgery,
Hospital La Timone, Aix Marseille
Univ, APHM, Marseille, France

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

As you know, glioma is the most common primary tumor of the central nervous system, and is characterized by rapid growth and aggressiveness; glioblastoma is one of the most dreaded brain tumors. There has been a commitment to drug development and new treatments for glioma, but progress has been limited, and the prognosis for patients with GBM remains poor. Inherent or acquired resistance to existing therapies, regional and heterogeneous blood glioma barriers, and the number of stem-cell-like cells within glioblastomas are challenges that are being actively addressed. These new approaches need to be summarized, especially regarding fundamental oncology approaches, and in the light of the new WHO brain tumor classification of 2021.

